Inhibition of PD-L2 glycosylation reduces epidermal growth factor receptor (EGFR) blocker cetuximab resistance in an in vivo model of HNSCC, and glycosylation levels can predict anti-EGFR efficacy [60]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.